These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 23908067

  • 1. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death.
    Inzitari D, Giusti B, Nencini P, Gori AM, Nesi M, Palumbo V, Piccardi B, Armillis A, Pracucci G, Bono G, Bovi P, Consoli D, Guidotti M, Nucera A, Massaro F, Micieli G, Orlandi G, Perini F, Tassi R, Tola MR, Sessa M, Toni D, Abbate R, MAGIC Study Group.
    Stroke; 2013 Oct; 44(10):2901-3. PubMed ID: 23908067
    [Abstract] [Full Text] [Related]

  • 2. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.
    Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ.
    Neurology; 2006 May 23; 66(10):1550-5. PubMed ID: 16717217
    [Abstract] [Full Text] [Related]

  • 3. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study.
    Kelly PJ, Morrow JD, Ning M, Koroshetz W, Lo EH, Terry E, Milne GL, Hubbard J, Lee H, Stevenson E, Lederer M, Furie KL.
    Stroke; 2008 Jan 23; 39(1):100-4. PubMed ID: 18063832
    [Abstract] [Full Text] [Related]

  • 4. Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.
    Muhammad S, Planz O, Schwaninger M.
    Cerebrovasc Dis Extra; 2016 Jan 23; 6(2):50-9. PubMed ID: 27560521
    [Abstract] [Full Text] [Related]

  • 5. Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase.
    Tsuruoka A, Atsumi C, Mizukami H, Imai T, Hagiwara Y, Hasegawa Y.
    J Stroke Cerebrovasc Dis; 2014 Jan 23; 23(10):2894-2899. PubMed ID: 25282183
    [Abstract] [Full Text] [Related]

  • 6. Fibrinogen decrease after intravenous thrombolysis in ischemic stroke patients is a risk factor for intracerebral hemorrhage.
    Vandelli L, Marietta M, Gambini M, Cavazzuti M, Trenti T, Cenci MA, Casoni F, Bigliardi G, Pentore R, Nichelli P, Zini A.
    J Stroke Cerebrovasc Dis; 2015 Feb 23; 24(2):394-400. PubMed ID: 25497721
    [Abstract] [Full Text] [Related]

  • 7. Computed Tomography--Verified Leukoaraiosis Is a Risk Factor for Post-thrombolytic Hemorrhage.
    Willer L, Havsteen I, Ovesen C, Christensen AF, Christensen H.
    J Stroke Cerebrovasc Dis; 2015 Jun 23; 24(6):1126-30. PubMed ID: 25920756
    [Abstract] [Full Text] [Related]

  • 8. A case-controlled comparison of thrombolysis outcomes between wake-up and known time of onset ischemic stroke patients.
    Manawadu D, Bodla S, Jarosz J, Keep J, Kalra L.
    Stroke; 2013 Aug 23; 44(8):2226-31. PubMed ID: 23723307
    [Abstract] [Full Text] [Related]

  • 9. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours.
    Thomalla G, Sobesky J, Köhrmann M, Fiebach JB, Fiehler J, Zaro Weber O, Kruetzelmann A, Kucinski T, Rosenkranz M, Röther J, Schellinger PD.
    Stroke; 2007 Feb 23; 38(2):313-8. PubMed ID: 17204683
    [Abstract] [Full Text] [Related]

  • 10. Lipid profile, lipid-lowering medications, and intracerebral hemorrhage after tPA in get with the guidelines-stroke.
    Messé SR, Pervez MA, Smith EE, Siddique KA, Hellkamp AS, Saver JL, Bhatt DL, Fonarow GC, Peterson ED, Schwamm LH.
    Stroke; 2013 May 23; 44(5):1354-9. PubMed ID: 23493734
    [Abstract] [Full Text] [Related]

  • 11. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
    Kono S, Deguchi K, Morimoto N, Kurata T, Yamashita T, Ikeda Y, Narai H, Manabe Y, Takao Y, Kawada S, Kashihara K, Takehisa Y, Inoue S, Kiriyama H, Abe K.
    J Stroke Cerebrovasc Dis; 2013 Oct 23; 22(7):1175-83. PubMed ID: 23507462
    [Abstract] [Full Text] [Related]

  • 12. Predicting clinical outcomes after thrombolysis using the iScore: results from the Virtual International Stroke Trials Archive.
    Saposnik G, Reeves MJ, Johnston SC, Bath PM, Ovbiagele B, VISTA Collaboration.
    Stroke; 2013 Oct 23; 44(10):2755-9. PubMed ID: 23887844
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Extension of the thrombolytic time window with minocycline in experimental stroke.
    Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH.
    Stroke; 2008 Dec 23; 39(12):3372-7. PubMed ID: 18927459
    [Abstract] [Full Text] [Related]

  • 19. Pretreatment diffusion-weighted imaging lesion volume predicts favorable outcome after intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke.
    Kruetzelmann A, Köhrmann M, Sobesky J, Cheng B, Rosenkranz M, Röther J, Schellinger PD, Ringleb P, Gerloff C, Fiehler J, Thomalla G.
    Stroke; 2011 May 23; 42(5):1251-4. PubMed ID: 21415399
    [Abstract] [Full Text] [Related]

  • 20. THRIVE score predicts ischemic stroke outcomes and thrombolytic hemorrhage risk in VISTA.
    Flint AC, Faigeles BS, Cullen SP, Kamel H, Rao VA, Gupta R, Smith WS, Bath PM, Donnan GA, VISTA Collaboration.
    Stroke; 2013 Dec 23; 44(12):3365-9. PubMed ID: 24072004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.